COX-2-specific inhibitors - The emergence of a new class of analgesic and anti-inflammatory drugs

Clinical Rheumatology

Volumn 19, Issue 5, 2000, Pages 331-343

  Everts, B ^a   Wahrborg P ^a   Hedner, T ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Celecoxib; Cox 2 specific inhibitors; Inflammatory disease; NSAID; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; METHOTREXATE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; RIFAMPICIN; ROFECOXIB; WARFARIN;

ASTHMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DESIGN; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY INJURY; NOMENCLATURE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; ULCER;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 0033802911     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670070024     Document Type: Review

References (131)

1. The early clinical history of salicylates in rheumatology and pain
2. Anti-inflammatory drugs and their mechanisms of action
3. Review article: COX-II inhibitors - A new generation of safer NSAIDs?
4. COX-2 inhibitors. Potential for reducing NSAID side-effects in treating inflammatory diseases
5. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
6. The synthesis and inhibition of eicosanoids and inflammation
7. Arachidonic acid metabolism
8. The eicosanoids and their biochemical mechanisms of action
9. Towards a better aspirin
10. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
11. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
12. The role of antiinflammatory drugs in the prevention and treatment of Alzheimer's disease
13. Aspirin use and reduced risk of fatal colon cancer
14. Prevention of gastrointestinal cancer - The potential role of NSAIDs in colorectal cancer
15. Aspirin as an antiplatelet drug
16. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebovascular ischaemic events
17. Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation
18. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
19. Aspirin selectively inhibits prostaglandin production in human platelets
20. Indomethacin and aspirin abolish prostaglandin release from spleen
21. Purification of the cyclo-oxygenase that forms prostaglandins. Demonstration of the two forms of iron in the holoenzyme
22. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
23. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
24. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
25. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
26. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
27. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
28. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclo oxygenase-related protein
29. TIS10. A phorbol ester tumor promotor-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
30. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles
31. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
32. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory drugs
33. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
34. Transforming growth factor beta 1 auguments mitogen-induced prostaglandin synthesis and expression of the TIS10/ prostaglandin synthase 2 gene both in Swiss 3T3 cells and in murine embryo fibroblasts
35. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
36. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macmphages and blood monocytes
37. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo
38. Cyclooxygenase-1 and-2 expression in rheumatoid tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids
39. Differential regulation of inducible and constitutive prostaglandin endooperoxide synthase in osteoblastic MC3T3-E1 cells
40. Regulation of prostaglandin endoperoxidase synthase gene expression in rat mesangial cell by interleukin-1 beta
41. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells
42. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester
43. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
44. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
45. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignement
46. Editorial
47. NSAIDs, Cox-2 inhibitors, and the gut
48. Nimesulide: A selective cyclooxygenase 2 inhibitor antiinflammatory drug
49. Non-steroidal anti-inflammatory drugs and ulcers: Facts and figures multiply but do they add up?
50. Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales
51. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach
52. Gastric ulcer, duodenal ulcer and gastric carcinoma: A case-control study of certain social and environmental factors
53. Upper gastrointestinal disease in rheumatid arthritis
54. Analgesic-antipyretics and inflammatory agents: Drugs employed in the treatment of rheumatid arthritis and gout
55. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
56. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
57. Cytoprotection by prostaglandins
58. Arachidonic acid stimulation of mucus production by rat gastric cultured cells
59. Prostaglandin protects isolated guinea pig chief cells against ethanol injury via an increase in diacylglycerol
60. The defensive role played by the gastric microcirculation
61. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
62. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
63. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
64. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutro-phil-dependent process
65. Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats
66. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit
67. ICAM-1 and P-selectin expression in a model of NSAID-induced gastropathy
68. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumour necrosis factor alpha
69. Role of tumour necrosis factor-α release and leukocyte margination in indomethacin-induced gastric injury in rats
70. Tumour necrosis factor mediation of NSAID-induced gastric damage: Role of leukocyte adherence
71. TNFα processing enzyme inhibitors prevent aspirin-induced TNFα release and protect against gastric mucosal injury in rats
72. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
73. Cyclooxygenase-2 is associated with the macula densa of the kidney and increases with salt restriction
74. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle. Selective inhibitions of the medullary portion
75. Role of prostaglandin E (PGE) in the modulation of action of vasopressin on water flow in the urinary bladder of the toad and mammalian kidney
76. Assessing the benefits and risks of drugs. The example of NSAIDs
77. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of a 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-prazol-l-yl] benzenesulfonamide (SC-58635, celecoxib)
78. Specific COX-2 inhibitors: From bench to bedside
79. Outcome of specific COX-2 inhibition in rheumatoid arthritis
80. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post surgical pain model
81. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635; SC) in patients with post surgical dental pain
82. Preliminary study of the safety and efficacy of SC-58635, a novel cycklooxygenase 2 inhibitor
83. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor
84. Selective inhibition of cyclooxygenase-2 (COX-2) with MG-0966 (250 mg qd) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid
85. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor
86. Treatment of osteoarthritis with celecoxib, a cylooxygenase-2 inhibitor: A randomised controlled trial
87. Pain management in osteoarthritis: The role of COX-2 inhibitors
88. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis in a short-term pilot study
89. Safety and efficacy of celecoxib, a specific COX-2 inhibitor
90. Endoscopic and tolerability, results from a study of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis
91. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis
92. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the denta pain model
93. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966
94. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
95. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a six-week controlled clinical trial
96. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial
97. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg qd) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid
98. COX-2 specific inhibition with MK-0966 or 50 mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo or ibuprofen 800 mg tid
99. Effects of some naturally occuring prostanoids and some cyclooxygenase inhibitors on the contraction of the human uterine segment in vivo
100. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
101. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Review
102. COX-2 inhibitors
103. Tissue prostaglandin levels in familiar adenomatous polyposis patients treated with sulindac
104. Treatment of colonic and rectal adenomas with sulindac in familiar adenomatous polyposis
105. Effects of sulindac on sporadic colorectal adenomatous polyps
106. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
107. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
108. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
109. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
110. Inhibition of cyclooxygenase-2
111. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2)
112. Neuroinflammatory mechanisms in Alzheimer's disease: New opportunities for drug discovery
113. Risk of Alzheimer's disease and duration of NSAID use
114. Inflammatory and immunological mechanisms in Alzheimer's disease
115. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer's disease
116. Prostaglandin G/H synthase-2 (cyclogenase-2) mRNA expression is decreased in Alzheimer's disease
117. Use of a cyclooxygenase type-2-selective non-steroidal antiinflammatory agent to prevent preterm delivery
118. Localization of prostaglandin H synthase typ 2 protein and mRNA in term human fetal membranes and decidua
119. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
120. Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors
121. Terphenyl cyclooxygenase-2 (COX-2) inhibitors: Optimization of the central ring and obiphenyl analogs
122. 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors
123. Synthesis, structure-activity relationsships, and in vivo evaluations of substituted ditert-butylphenoles as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4-and 1,2,4-thiadiazole series
124. Synthesis, structureactivity relationsships, and in vivo evaluations of substituted di-tert-butylphenoles as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series
125. Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: Novel inhibitors of COX-2
126. Covalent modification of cyclooxygenase (COX-2) inhibitors by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators
127. 1,2-Diarylpyrrolones as potent and selective inhibitors of cyclooxygenase-2
128. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol- 1-yl]benzenesulfonamide (SC-58635, celecoxib)
129. Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents
130. Diarylspiro[2,4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure-activity relationships